On September 10, 2026, in South San Francisco, Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotech firm focused on therapeutics for viral and liver ailments, shared plans for senior management to participate in the H.C. Wainwright & Co. 28th Annual Global Investment Conference. The presentation is scheduled for September 16, 2026, at 8:30 a.m. Eastern Time. This conference provides a platform to showcase the company's innovative approaches towards tackling severe viral and liver diseases.